Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Roche reports further sales growth in first nine months of 2017

Roche reports further sales growth in first nine months of 2017

19th October 2017

Roche has announced its financial results for the first nine months of 2017, during which it generated a sales total of 39.43 billion Swiss francs (30.64 billion pounds).

This represents a year-on-year increase of five percent, with growth attributed to the successful launch of several new products. Recently-launched medicines such as Ocrevus, Tecentriq and Alecensa accounted for more than half of the pharmaceutical division's growth.

The firm's diagnostics division also experienced a five percent sales increase, primarily due to its immunodiagnostics business.

Key highlights of the quarter include the receipt of regulatory approval for Tecentriq in two types of metastatic bladder cancer and metastatic lung cancer, as well as Gazyvaro for previously untreated advanced follicular lymphoma, and RoActemra for giant cell arteritis.

For the full year, the company expects sales to grow in the mid-single digit range at constant exchange rates.

Severin Schwan, Roche's chief executive officer, said: "Based on the strong sales growth of our pharmaceuticals and diagnostics divisions in the first nine months, I am confident that we will achieve our full-year targets."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.

We currently have 8 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.